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Introduction: Neo-adjuvant chemoradiotherapy is commonly used before surgery for rectal cancer. Very
low rectal cancers are still treated by abdominoperineal excision of the rectum (APER). Perineal wound
complications are common after APER. There is evidence that radiotherapy increases wound complica-
tions. We wished to examine the effect of preoperative radiotherapy (SCPRT) and long course chemo-
radiotherapy (LCCRT) on perineal wound complications.
Methods: We undertook a review of all patients undergoing APER at one institution between 2000 and
2010. Details of SCPRT, LCCRT and both minor and major wound complications were identiﬁed by
retrospective notes review.
Results: Of 74 patients suitable for analysis, 38 (51%) had recorded wound complications, with 23 (31%)
having major wound complications. 43 patients (58%) underwent LCCRT and 11 (15%) SCPRT. Overall
wound complications were more common in the LCCRT group than those receiving no treatment (58% vs
30%, p ¼ 0.03), and major wound complications more common after SCPRT than LCCRT (45% vs 35%,
p ¼ 0.04) or no treatment (45% vs 10%, p ¼ 0.04). Use of mesh led to more wound complications (71% vs
41%), but almost all of these patients received LCCRT.
Conclusions: Pre-operative LCCRT and SCPRT are both associated with increased perineal wound com-
plications after APER.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Abdominoperineal excision of the rectum (APER) was pop-
ularised in 1908 by Miles.1 It became the standard treatment for
rectal cancer, despite the introduction of anterior resection (AR) in
the 1930s. More recently, the technique of total mesorectal excision
(TME),2 a clearer deﬁnition of safe distal margin length3 and better
stapling devices4 have led to a decline in the usage of APER.5
APER has twomajor disadvantages over AR. Firstly, the patient is
left with a permanent stoma, which may decrease quality of life6e8
and has been identiﬁed by national bodies as a quality indicator in
colorectal cancer care.9,10 Secondly, perineal wound complications
are common after APER.11e14 These vary from minor complications
such as slight gaping or over-granulation of a small portion of the
wound, to major complications such as pelvic abscesses and/or full
wound failure.6 Major wound complications often require aciates Ltd. Published by Elsevier Ltprolonged stay in hospital with a delayed return to daily life. They
may also delay adjuvant treatment, which could lead to a poorer
long-term outcome.6
There is increasing evidence that preoperative radiotherapy (RT)
- with or without concurrent chemotherapy e is advantageous in
terms of local recurrence for rectal cancer (although a survival
advantage is not yet proven).15e20 There is also some evidence that
preoperative RT leads to an increased rate of perineal wound
complications after APER.21e27
The aim of this study was to look at the different effects of both
long-course and short-course pre-operative neo-adjuvant chemo-
radiotherapy on perineal wound healing after APER.We also looked
at other operative factors that could inﬂuence perineal healing. Our
results could help to identify future patients at high risk of wound
complications, in order that the risk can then be minimised.
2. Methods
All patients undergoing APER at our institution between 1st January 2000 and
31st December 2010 were identiﬁed retrospectively using electronic theatre records
and a manual search of consultant diaries. Patients who underwent APER ford. All rights reserved.
Table 1
Comparison of patients by wound complication.
Wound complications No wound
complications
Number of patients 38 36
Mean age 65 (range 36e83) 71 (range 48e90)
Open APER 27 (71%) 20 (56%)
Lap APER 7 (18%) 10 (28%)
Lap converted to open APER 2 (5%) 5 (14%)
Completion proctectomy 1 (3%) 1 (3%)
Histology
No residual cancer 5 (13%) 4 (11%)
Dukes A 10 (26%) 12 (33%)
Dukes B 10 (26%) 10 (27%)
Dukes C 10 (26%) 10 (27%)
Dukes D 1 (3%) 0
Not recorded 2 (5%) 0
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operation, or who died within thirty days of operation were excluded. Patient notes
were obtained and data extracted using a standard proforma, which included in-
formation on patient demographics, neoadjuvant therapy, histology, use of a drain or
mesh at operation, perineal wound complications, treatment of wound complica-
tions, repeat surgery, 30 day morbidity, length of inpatient stay and subsequent
mortality.
APER was performed either as a one or two surgeon procedure using a standard
technique, with some procedures utilising laparoscopic mobilisation. Several
different surgeons carried out the procedure, all at a single hospital site. The tech-
nique of extra-levator APER (ELAPER) and prone operation for the perineal
component were both introduced towards the end of the study period.
Perineal wound complications were identiﬁed by a detailed search of the
contemporary medical and nursing notes as well as post-operative clinic letters. Any
mention of perineal wound that suggested that it was not clean, healthy and dry was
documented as a “complication”. Complications noted included slight opening of
the skin edges, wound breakdown, wound sinus, wound collection, discharge,
slough, granuloma and communication with a pelvic collection. These were then
grouped into ‘minor’ complications (granulomas, discharge, slough, slight opening)
and ‘major’ complications (wound opening, collections, delayed healing).
Neo-adjuvant radiotherapy was given in two ways at our institution over this
time period. Most commonly in patients undergoing an APER it was given as a long
course of chemoradiation (LCCRT) using 45 Gy in 25 fractions delivered over ﬁve
weeks, with concurrent ﬂuoropyrimidine-based chemotherapy (5-ﬂuorouracil or
capecitabine-based), which was then followed by a gap of 6e8 weeks before APER.
Some patients received short course pre-operative radiotherapy (SCPRT) alone,
25 Gy in 5 fractions over one week, followed by surgery usually within one week.
Most patients in the current study were staged pre-operatively using pelvic MRI.
LCCRTwas used in patients whose disease threatened (within 2mm) or involved the
mesorectal fascia or anal sphincter/levator complex.
Statistical analysis was performed using Microsoft Excel, Softonic OpenStat
software; multivariate analysis used John C. Pezzullo and Kevin M. Sullivan’s online
logistic regression calculator (http://statpages.org/logistic.html). Univariate analysis
between perineal wound complications and categorical variables were performed
using Fisher’s exact probability test or the chi-squared test as appropriate. Contin-
uous variables were divided into ranges for categorical analysis. Incomplete data
were analysed based on what data was available and excluded only when data was
missing. A p value <0.05 was considered signiﬁcant.
3. Results
We identiﬁed 100 possible patients recorded as undergoing
APER during the study period from theatre records. Notes for 5
patients (4 deceased) were misﬁled or unobtainable. Sixteen pa-
tients were operated on for inﬂammatory bowel disease, 3 had
wounds left open at ﬁrst operation and 2 died within 30 days,
leaving 74 patients suitable for further analysis (Fig. 1). Mean age of
the patients was 68 years (standard deviation - SD - 12) at the time
of surgery, and 48 (65%) were male.
Perineal wound complications were recorded in 38 patients
(51%). Histological stage of cancer was similar between those with
wound complications and those without. Average age was signiﬁ-
cantly higher in those patients without wound complications
(p ¼ 0.026; Table 1).Fig. 1. Study ﬂow chart.Fifteen patients (39%) had minor complications (8 slight open-
ing, 6 discharge or slough, 1 granulomas) and the remaining 23
(31% of all patients) had major complications (18 wound break-
down, 3 infection with collection, 1 persistent wound sinuses, 1
prolonged discharge with pain). Nine patients (12% of total, 27% of
those with wound problems) underwent a second surgical proce-
dure for perineal wound complications (Table 2).
3.1. Preoperative radiotherapy
Fifty-four patients received pre-operative radiotherapy (73%). Of
these, the majority (43 patients) had LCCRT using 45 Gy in 25 daily
fractions over 5 weeks (41 patients) or 54 Gy in 30 fractions over 6
weeks (2 patients). Forty-two of these 43 patients also received
chemotherapy concurrent with their radiotherapy, although one of
these failed to tolerate chemotherapy after the ﬁrst dose (5FU). The
remaining patient refused chemotherapy but accepted radio-
therapy alone. All patients were analysed on an intention-to-treat
basis.
The most common drug used was 5-ﬂuorouracil (27/42), either
alone (23), with irinotecan (as part of the NWCOG-1 trial28 e 3
patients), or with folinic acid (1). The remainder received capeci-
tabine (15/42), either alone (5) or with irinotecan (as part of the
NWCOG-2 trial29 e 10 patients).
Eleven patients underwent SCPRT using 25 Gy in 5 daily frac-
tions over 1 week. No patients who had SCPRT had pre-operative
chemotherapy.
Twenty patients (27%) did not receive neoadjuvant therapy
(Table 3).
The number of patients with any wound complication after
LCCRT (on an intention-to-treat basis) was 25 of 43 (58%) compared
to 6 of 20 (30%) in the group who did not undergo any neoadjuvant
treatment (p ¼ 0.03 - Fisher’s exact test). There was a trend for
patients undergoing SCPRT to have wound complications 7 of 11
(63%) although this did not quite reach signiﬁcance whenTable 2
Wound complications.
Total Requiring operation





Wound breakdown 18 6
Collection 3 3




Number 43 (58%) 11 (15%) 20 (27%)
Mesh 18 (42%) 2 (18%) 1 (5%)
Drain 37 (86%) 10 (91%) 13 (65%)
Wound complications 25 (58%)a 7 (63%)b 6 (30%)
Major wound complications 15 (35%) 5 (45%)c 2 (10%)
a p<0.05 when compared to no neoadjuvant therapy.
b p ¼ 0.07 when compared to no neoadjuvant therapy.
c p<0.05 when compared to LCCRT or no neoadjuvant therapy.
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(p ¼ 0.07). There was no difference in the rate of all wound com-
plications between LCCRT and SCPRT (p ¼ 0.75; Table 3).
Fifteen of 43 patients in the LCCRT group had major wound
complications (35%), compared with 2 of 20 who did not receive
neoadjuvant therapy (10%) e there was no signiﬁcant difference
(p ¼ 0.99). Five of 11 patients in the SCPRT group had major wound
complications (45%), which was signiﬁcantly higher than the LCCRT
group (p ¼ 0.04) and the group without neoadjuvant therapy
(p ¼ 0.04; Table 3).
Of the 42 patients receiving pre-operative chemotherapy, 13
patients received a doublet regimen containing irinotecan plus a
ﬂuoropyrimidine (5FU or capecitabine). Five patients in this group
(38%) had wound complications, compared with 20 of 29 (69%)
receiving chemoradiotherapy regimens containing a single agent
ﬂuoropyrimidine. This difference did not quite reach statistical
signiﬁcance (p ¼ 0.06, Fisher’s exact test). Three of 13 patients
receiving irinotecan had major wound complications (23%)
compared to 12 of 29 receiving a single agent (41%) which was not a
signiﬁcant difference (p ¼ 0.94).3.2. Stage of disease
Information on pre-operative staging was unfortunately unob-
tainable in some patients (mostly in patients early in the study
period) and hence has not been used for analysis.
In terms of post-operative staging, a histology report was un-
obtainable for one patient. For the remainder, 21 patients were
node positive, or had metastases at the time of operation (Dukes C
or D, Tx N1 or 2 orM1). Of these 11 (52%) hadwound complications,
compared with 26 (50%, p ¼ 0.52) of N0 M0 patients.3.3. Use of mesh
Twenty-one patients had a mesh placed as part of the APER
operation. Of these, 15 were porcine dermal collagen (14
Permacol, Covidien; 1 CollaMend, Bard), 3 porcine small in-
testinal submucosa (SurgiSIS, Cook), and 3 polyglactin 910
(Vicryl, Ethicon). There was no record of why mesh had been
chosen in these patients, and equally no record of why it was
omitted in other patients.
Fifteen of 21 patients in whom mesh was used had wound
problems (71%) compared with 23 of 53 (43%) in the group that did
not receive mesh (p¼ 0.02). Of note however is that the majority of
the patients in whom mesh was used received either SCPRT (2) or
CRT (18).
When comparing patients who received standard pre-operative
CRT and mesh with those who received CRT alone, there was no
signiﬁcant difference in wound complications (12 of 18 (67%) vs. 13
of 25 (0.52%), p ¼ 0.8), suggesting that pre-operative CRT was the
most important factor.3.4. Use of drains
Perineal wound drains were recorded either in the operative
note, contemporary medical record or nursing notes as being
placed, present and/or removed in 60 patients. In patients without
drains, wound complications occurred in 8 of 14 (57%), and in 30 of
60 where drains were placed (50%, p ¼ 0.42).
3.5. Multivariate analysis
A multivariate analysis was performed, looking at neoadjuvant
therapy, age, sex, use of drains and use of mesh as possible factors.
When all perineal wound complications were considered, age
(p ¼ 0.047, OR 0.63), mesh (p ¼ 0.027, OR 3.26) and neoadjuvant
therapy (p ¼ 0.029, OR 3.39) were identiﬁed as predictors. In this
analysis the combination of younger age and mesh was a strong
independent predictor of complications (p ¼ 0.0156).
When major wound complications were considered, only neo-
adjuvant therapy as a signiﬁcant factor (p ¼ 0.01, OR 5.73).
Excluding short course radiotherapy patients from the analysis
showed similar results, with only LCCRT as a signiﬁcant predictor of
all wound complications (p ¼ 0.018, OR 5.33). For major wounds,
again LCCRT was the only signiﬁcant factor (p ¼ 0.018), although
adding use of a drain improved the prediction of wound compli-
cations very slightly (p ¼ 0.017). Numbers in the SCPRT group were
too small to examine independently via logistic regression,
although it should be noted that all three patients who received
mesh had a wound infection.
4. Discussion
Wound complications after APER for low rectal cancer result in a
high morbidity for patients and are both common and potentially
serious. Previous studies have shown an increased likelihood of
wound complications after long-course neoadjuvant radiotherapy,
with or without chemotherapy,21e23,27 although this ﬁnding is not
universal.30e32
The current studyconﬁrms that a 5-week courseof external beam
LCCRT combined with either concurrent 5-ﬂuorouracil or capecita-
bine chemotherapy signiﬁcantly increases the likelihood of overall
perineal wound complication compared to patients not receiving
CRT. Irinotecan did not appear to increase the risk of any wound
complications. However the numbers are small in each of these
subgroups and a larger (or pooled) analysis would be needed to
conﬁrm these results. If this ﬁnding is conﬁrmed with larger
numbers of patients however, then this is relevant to theUKphase III
ARISTOTLE trial which aims to accrue a total of 920 patients and
started recruitment in early 2012. This trial randomises patientswith
MRI-deﬁned locally advanced rectal cancer to receive LCCRT using
concurrent capecitabine with or without additional irinotecan.
In the Dutch TME randomised trial it was shown that SCPRT
causes a statistically signiﬁcantly increased rate of perineal wound
complications following APER (26%) compared to those who did
not receive any pre-operative radiotherapy (18%).33 This observa-
tionwas repeated in the UKCR07 trial (35% vs. 22%).18 Our study has
shown a signiﬁcant increase in major wound complications after
SCPRT, both compared to LCCRT and no neo-adjuvant treatment.
There was also a trend for an increase in all wound complications.
However the numbers are small and further data would be needed
to corroborate this.
Use of mesh or drains, which were placed according to the sur-
geon’s judgement, did not appear to inﬂuence wound healing
beyond the preoperative LCCRT or SCPRT given in these groups. In
particular, 90% of patients inwhommeshwas placed received LCCRT
e thismay be because these tumoursweremore advanced. Certainly
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adopted. Histological nodal status and (radiological) metastases did
not inﬂuence wound complications. Mean (and maximum) age was
greater in the group without wound complications, suggesting that
this equally had no effect. Multivariate analysis has suggested that
age, mesh and drain may all have a small effect in some cases.
Because the numbers in each subgroup were small they should be
interpreted with caution and further studies with larger numbers
would be required to conﬁrm the results.
Our study has a number of limitations. The numbers are small
and any ﬁndings must be interpreted in this context. In particular,
the number of patients undergoing SCPRT was very small. Despite
this we found a signiﬁcant increase in major perineal wound
complications and a trend towards an increase in all perineal
wound complications.
This is a retrospective, non-randomised study. However,
because pre-operative CRT is established as a standard of care in the
treatment of low rectal cancer it is unlikely that randomised data
will become available in the future comparing CRT with no treat-
ment. Our report represents an audit of APER complications and the
relationship to LCCRT and SCPRT use in a ‘real life’ non-trial setting.
The groups in the study may not be directly comparable. The
reasons that patients did not undergo neoadjuvant therapy were
not always clear. Possible reasons include T1 or T2 tumours not
requiring therapy, patient choice or contraindications to neo-
adjuvant treatment. The operative strategy varied between surgeon
and over time, and included ‘standard’ APER, laparoscopic pro-
cedures and the ELAPER procedure.
The rate of wound complications (51%) was high compared to
previous studies. Previously reported rates vary between 14%30,32
and 47%.26 Our high percentage may be due to the low threshold
for reporting complications (any mention of wound problems in
themedical or nursing record). However, more than a third of these
(14 of 38, 37%) required no treatment other than topical dressings,
with a further 3 (8%) receiving antibiotics or silver nitrate and no
other intervention. It is possible that these patients would not be
recorded in a prospective trial as having a wound complication as
their problems (‘slight’ wound opening, discharge) are subjective.
However even if these groups are discounted that still leaves 21 of
74 patients (28%) with more signiﬁcant wound complications,
which is still relatively high. One possible explanation is the high
percent of the APER patients who received pre-operative LCCRT or
SCPRT (55 of 74, 74%).
5. Conclusions
Pre-operative LCCRT is signiﬁcantly associated with an increase
in perineal wound breakdown, irrespective of use of mesh, drains
and stage of disease. Pre-operative SCPRT also increases the likeli-
hood of a major perineal wound complication. Further studies and
meta-analysis are needed to conﬁrm this data and also to consider
the effect that wound complications have on overall and disease-
free survival.
Patients undergoing neoadjuvant therapy should be warned of
the increased risk of perineal wound problems. Unconventional
techniques such as primary vacuum therapy or skin ﬂaps may need
to be considered in patients undergoing pre-operative LCCRT and
SCPRT who will then undergo abdominoperineal excision of the
rectum.
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